Zhen Zhao1, Jeffrey Basilio1, Steven Hanson2, Randie R Little2, Anne E Sumner3, David B Sacks4. 1. Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, United States. 2. Department of Pathology and Anatomical Sciences, University of Missouri, Columbia, MO, United States. 3. Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, United States. Electronic address: annes@intra.niddk.nih.gov. 4. Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, United States. Electronic address: david.sacks2@nih.gov.
Abstract
BACKGROUND: Hemoglobin A1c (HbA1c) is used to monitor long-term glycemic control in individuals with diabetes, guide therapy, predict the risk of microvascular complications, and more recently to diagnose diabetes. An automated liquid-flow capillary electrophoresis method was recently developed to measure HbA1c using the Capillarys 2 Flex Piercing instrument. METHODS: Analytical evaluation was performed at 2 clinical centers. A clinical analysis was conducted in 109 African-born individuals, 24% of whom have variant hemoglobin (HbAS or HbAC). Abnormal glucose tolerance (which includes both diabetes and prediabetes) was defined as 2h glucose of ≥ 140 mg/dl (7.8 mmol/l) during an oral glucose tolerance test. RESULTS: Interlaboratory CVs were ≤ 2.1%. The method showed satisfactory correlation with 2 other analyzers that measure HbA1c by high-performance liquid chromatography. Neither labile HbA1c, carbamylated hemoglobin, uremia, bilirubin nor common hemoglobin variants (HbC/HbS/HbE) interfered. Forty-five individuals (41%) had abnormal glucose tolerance. The sensitivity of HbA1c for diagnosing abnormal glucose tolerance was 38%, 36% and 42% for total, normal and variant hemoglobin groups, respectively. CONCLUSIONS: The analytical performance of HbA1c on the Capillarys 2 is suitable for clinical application. Variant hemoglobin in Africans did not interfere with the detection of abnormal glucose tolerance by HbA1c measured on the Capillarys 2. Published by Elsevier B.V.
BACKGROUND: Hemoglobin A1c (HbA1c) is used to monitor long-term glycemic control in individuals with diabetes, guide therapy, predict the risk of microvascular complications, and more recently to diagnose diabetes. An automated liquid-flow capillary electrophoresis method was recently developed to measure HbA1c using the Capillarys 2 Flex Piercing instrument. METHODS: Analytical evaluation was performed at 2 clinical centers. A clinical analysis was conducted in 109 African-born individuals, 24% of whom have variant hemoglobin (HbAS or HbAC). Abnormal glucose tolerance (which includes both diabetes and prediabetes) was defined as 2h glucose of ≥ 140 mg/dl (7.8 mmol/l) during an oral glucose tolerance test. RESULTS: Interlaboratory CVs were ≤ 2.1%. The method showed satisfactory correlation with 2 other analyzers that measure HbA1c by high-performance liquid chromatography. Neither labile HbA1c, carbamylated hemoglobin, uremia, bilirubin nor common hemoglobin variants (HbC/HbS/HbE) interfered. Forty-five individuals (41%) had abnormal glucose tolerance. The sensitivity of HbA1c for diagnosing abnormal glucose tolerance was 38%, 36% and 42% for total, normal and variant hemoglobin groups, respectively. CONCLUSIONS: The analytical performance of HbA1c on the Capillarys 2 is suitable for clinical application. Variant hemoglobin in Africans did not interfere with the detection of abnormal glucose tolerance by HbA1c measured on the Capillarys 2. Published by Elsevier B.V.
Authors: Mariela Marinova; Sara Altinier; Anna Caldini; Gabriella Passerini; Giorgio Pizzagalli; Marco Brogi; Martina Zaninotto; Ferruccio Ceriotti; Mario Plebani Journal: Clin Chim Acta Date: 2013-06-20 Impact factor: 3.786
Authors: David B Sacks; Mark Arnold; George L Bakris; David E Bruns; Andrea Rita Horvath; M Sue Kirkman; Ake Lernmark; Boyd E Metzger; David M Nathan Journal: Clin Chem Date: 2011-05-26 Impact factor: 8.327
Authors: Chia-Ni Lin; Todd J Emery; Randie R Little; Steve E Hanson; Curt L Rohlfing; Stéphane Jaisson; Philippe Gillery; William L Roberts Journal: Clin Chim Acta Date: 2012-01-08 Impact factor: 3.786
Authors: Ugochi J Ukegbu; Darleen C Castillo; Michael G Knight; Madia Ricks; Bernard V Miller; Barbara M Onumah; Anne E Sumner Journal: Diabetes Care Date: 2011-08-26 Impact factor: 19.112